Narrative Review

Advances in muscle health and nutrition: A toolkit for healthcare professionals

Carla M. Prado a,*, Francesco Landi b, Samuel T.H. Chew c, Philip J. Atherton d, Jeroen Molinger e, f, Tobias Ruck g, Maria Cristina Gonzalez h

a Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, AB, Canada
b Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
c Centre of Metabolism, Ageing & Physiology (COMAP), Medical Research Council (MRC) Versus Arthritis Centre for Musculoskeletal Ageing Research (CAMAR), and National Institution for Health Research (NIHR) Biomedical Research Centre (BRC), School of Medicine, University of Nottingham, Nottingham, UK
d Department of Geriatric Medicine, Changi General Hospital, Singapore Health Services (Simei Campus), Singapore
e Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
f Erasmus Medical Center, University Rotterdam, Rotterdam, the Netherlands
g Post-graduate Program in Health and Behavior, Catholic University of Pelotas, and Post-graduate Program in Nutrition and Food, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil

© 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Abstract

Low muscle mass and malnutrition are prevalent conditions among adults of all ages, with any body weight or body mass index, and with acute or chronic conditions, including COVID-19. This article synthesizes the latest research advancements in muscle health and malnutrition, and their impact on immune function, and clinical outcomes. We provide a toolkit of illustrations and scientific information that healthcare professionals can use for knowledge translation, educating patients about the importance of identifying and treating low muscle mass and malnutrition. We focus on the emerging evidence of mitochondrial dysfunction in the context of aging and disease, as well as the cross-talk between skeletal muscle and the immune system. We address the importance of myosteatosis as a component of muscle composition, and discuss direct, indirect and surrogate assessments of muscle mass including ultrasound, computerized tomography, deuterated creatine dilution, and calf circumference. Assessments of muscle function are also included (handgrip strength, and physical performance tests). Finally, we address nutrition interventions to support anabolism, reduce catabolism, and improve patient outcomes. These include protein and amino acids, branched-chain amino acids, with a focus on leucine; β-hydroxy-β-methylbutyrate (HMB), vitamin D; n-3 polyunsaturated fatty acids (n-3 PUFA), polyphenols, and oral nutritional supplements. We concluded with recommendations for clinical practice and a call for action on research focusing on evaluating the impact of body composition assessments on targeted nutrition interventions, and consequently their ability to improve patient outcomes.

1. Introduction

Low muscle mass and malnutrition impact the health and well-being of many individuals, especially older adults and patients with acute and chronic diseases. As such, early detection and intervention are essential to counteract the detrimental effects of these conditions. The advent of body composition assessment has allowed researchers to define important characteristics and consequences of low muscle mass (Fig. 1). Since low muscle mass and malnutrition are often hidden in patients with normal weight or in...
those with excess adiposity, these conditions are frequently overlooked; therefore, such techniques are of significant value [1,2]. In fact, both malnutrition and low muscle mass are prevalent among young and older adults of any body weight or body mass index (BMI) and in any clinical condition, including COVID-19 [2–4]. They can also occur regardless of weight change [5]. Finally, low muscle mass and malnutrition are associated with impaired immune function and are independent predictors of adverse clinical outcomes, such as the ones highlighted in Fig. 2 [2,3,6–14].

Integrating assessment of muscle mass and malnutrition into clinical practice across the continuum of care is challenging but required for early identification of at-risk patients [2]. This would also allow for appropriate and personalized nutrition and exercise interventions in the context of multimodal therapy (Fig. 1), which can be delivered by a multidisciplinary team [15,16]. Efforts to translate research-based evidence to daily clinical practice takes time but eventually becomes reality, improving patient care and clinical outcomes. For example, it took 50 years after the term “osteoporosis” was coined and defined for osteoporosis to be recognized as a condition that is readily assessed and treated [17]. (Fig. S1).

While our understanding of both the importance of poor muscle health and nutritional status as therapeutic target/approach has grown, these conditions are still underappreciated, with a wide gap between research findings and evidence-based clinical practice. To bridge this gap, or translate the knowledge from research into clinical practice, there is a need for more high-quality studies highlighting the value of assessing and treating these conditions; increased awareness; and a pathway for clinical practice implementation. Regarding increased awareness, common barriers are: limited access to information sources; high volumes of evidence but limited dedicated time to read; and limited research interpretation skills [18].

This article reports on the 119th Abbott Nutrition Research Conference held in June 2021. This is an annual global research conference on key topics in pediatric and adult nutrition. The objective of this edition was to bring together global experts to provide healthcare professionals with a summary of the latest advances in muscle mass and malnutrition research in the contexts of aging and disease. In addition to synthesizing and updating the scientific literature discussed at the meeting, our goal with this publication is to enable continued knowledge transfer beyond the conference by providing a resource that healthcare professionals can use as educational materials on this topic. As such, this article is a “toolkit” comprising scientific information and illustrations that can facilitate knowledge transfer on the identification, importance, and treatment of low muscle mass and malnutrition.

To improve understanding of the content hereby discussed, we first define some important concepts. For instance, several terms are commonly employed to describe muscle mass, such as lean soft tissue, fat-free mass, and skeletal muscle. Although these terms are often used interchangeably, they depict different body compartments containing skeletal muscle [19] and are specific to the techniques employed for body composition assessment. Here, we use precise terminology to describe body compartments containing skeletal muscle, and this may therefore differ from original studies. We also used the term “muscle mass” generically to describe lean soft tissue, fat-free mass, and skeletal muscle. To avoid the confusion between primary and secondary sarcopenia (terms defined elsewhere [20]), we will hereby use the term “muscle health” to depict adequate muscle mass, composition (i.e., no myosteatosis), and/or function (i.e., strength and physical performance). We will use the term “sarcopenia” to depict conditions of low muscle mass and function concurrently [21,22].

![Fig. 1. Chronology of malnutrition, muscle, and body composition definitions. The advent of new technology to assess body composition has allowed us to understand that low muscle mass and malnutrition: (1) are not only observed in people who have an emaciated appearance; (2) may be hidden conditions; (3) are prevalent at any body weight and age; (4) are particularly prevalent in older adults and across the continuum of care; and (5) are associated with immunity, and are independent predictors of clinical outcomes. Also, (6) COVID-19 has capitalized the importance of low muscle mass. Future research is required to (7) implement body composition assessment in clinical settings, (8) explore the use of targeted nutrition interventions to prevent and treat low muscle mass and malnutrition, and (9) understand the effects of concurrent nutrition and exercise interventions to maximize anabolic potential.](image-url)
2. Toward a better understanding of low muscle mass and malnutrition as overlapping conditions

Low muscle mass is a defining criterion for the diagnosis of malnutrition, sarcopenia, and cachexia, according to current consensus definitions [21–25]. Aside from the phenotype of low muscle mass, these conditions share common characteristics including etiological factors, such as aging, low physical activity, reduced nutrient intake and absorption, and systemic inflammation (Fig. 3). Given these similarities, malnutrition and muscle-related conditions (i.e., low muscle mass, myosteatosis [or fatty infiltration of muscle tissue], sarcopenia, cachexia, and frailty) should not be viewed as isolated entities but rather as conditions that can occur simultaneously or sequentially in some individuals. Most patients with malnutrition have low muscle mass or sarcopenia, but people with malnutrition do not necessarily need to have low muscle mass or sarcopenia [23,24]. Likewise, not all patients with low muscle mass or sarcopenia are malnourished. Malnutrition is often a precursor to sarcopenia as it leads to reduced physical function and unfavorable changes in body composition. For instance, malnutrition at baseline was associated with a four-fold increased risk of developing sarcopenia over a five-year period in community-dwelling older adults [26]. Consequently, sarcopenia can both precede frailty and be a component of frailty, which is a precursor to adverse outcomes; and both conditions often overlap with malnutrition [27,28].

Although low muscle mass and malnutrition can occur independently of each other, they frequently overlap, especially among hospitalized patients and those with chronic conditions such as cancer [1,29–31]. A recent systematic review and meta-analysis of 39 studies in older hospitalized patients (n = 8868) found that almost 50% of patients were simultaneously diagnosed with malnutrition and frailty, and 42% were diagnosed with malnutrition and sarcopenia, highlighting their concurrent presence [29]. Among patients with head and neck cancer (61% with advanced cancer) at diagnosis, malnutrition was found in 14% of those with
concurrent low muscle mass and myosteatosis; only 7% of patients presented with low muscle mass alone [30]. Furthermore, the prevalence of malnutrition, frailty, and sarcopenia ranged from 44% to 69% among patients with cachexia [31]. The overlap between conditions has also been described in a recent general population cohort study (n = 111,983); among individuals diagnosed with malnutrition, 68% also had cachexia, 91% had sarcopenia, and 92% had frailty [32]. The cumulative impact of having these conditions simultaneously remains to be established, but evidence suggests worse health outcomes. For instance, hospitalized older patients with concurrent malnutrition and sarcopenia had a greater hazard ratio for shorter survival than those with malnutrition alone [33].

3. Emerging evidence on the pathophysiology of low muscle mass

Low muscle mass is prevalent among older adults as a consequence of the aging process and can be exacerbated in patients (of any age) with chronic disease, acute illness, or injuries. As low muscle mass is a common component of malnutrition, sarcopenia, and cachexia, understanding its pathophysiology is relevant for advancing diagnosis and treatment. Immobility and catabolic conditions induce muscle loss when protein degradation pathways become active: the ubiquitin-proteasome system, which degrades most myofibrillar proteins; and the autophagy-lysosome system, which bulk degrades cellular components and organelles in the cytoplasm (e.g., mitochondria) [34,35]. Malnutrition and acute and chronic diseases are accelerators for muscle loss (Fig. 4). While the pathophysiology of muscle wasting is incompletely understood, factors contributing to muscle catabolism have been the focus of intensive research in the last decades, and these include abnormalities in muscle proteostasis, i.e., fasted/fed-state and disuse regulation of muscle protein synthesis (MPS) and muscle protein breakdown (MPB) [36,37], glucose and insulin homeostasis [38], inflammation [38,39], neuromuscular [40], and/or microvascular function [41,42]. These concepts can be further reviewed elsewhere [43,44].

In relation to emerging facets of muscle atrophy, mitochondrial dysfunction is increasingly recognized as an important metabolic regulator [45,46]. In the context of aging, several skeletal muscle mitochondrial processes are impaired, including mitochondrial bioenergetics, as well as mitochondrial synthesis and breakdown (“mitophagy”) [47,48]. Mechanisms contributing to these mitochondrial modifications are reviewed elsewhere [49–51]. Notably, impaired mitochondrial function has been associated with both reduced muscle mass and strength. Although most of the evidence is based on animal experiments, there is a considerable body of research investigating alterations of mitochondrial processes in individuals with low muscle mass and/or function [49]. For instance, a recent study using genome-wide transcriptional profiling demonstrated that reduced mitochondrial bioenergetic capacity in muscle was the main factor distinguishing the presence of sarcopenia in older adults [52]. Moreover, differences in mitochondrial function of respiratory muscles were found across body composition phenotypes in patients undergoing lung resections: those with concurrent low muscle mass and high adiposity (i.e., sarcopenic obesity) had the lowest expression of markers for mitochondrial dynamics (i.e., biogenesis, fusion, and fission), compared to other phenotypes [53].

Mitochondrial dysfunction also exists in other acute and chronic conditions, such as cancer and sepsis [54]. The rapid muscle wasting in critical illness may also be partly due to inflammation-mediated mitochondrial dysfunction, with altered metabolism causing protein catabolism and suppressed lipid metabolism and therefore, myosteatosis [46]. With myosteatosis, blood flow to muscle is reduced giving rise to metabolic dysfunction, including insulin resistance, inflammation, and the loss of muscle mass and function [55].

3.1. Cross-talk between muscle and immune system

The cross-talk between skeletal muscle, as the largest organ in the body, and the immune system is also an emerging theme. Indeed, muscle is no longer seen as a passive target of the immune system but as an active player that regulates both innate and adaptive immune responses [56]. Three main mechanisms of interaction between skeletal muscle and immune cells have been discussed in the literature, including the release of myokines,
expression of cell surface molecules, and cell to cell interaction [56–58]. In addition to contributing to sarcopenia and mitochondrial dysfunction, aging also affects the immune system by impairing these mechanisms of interaction, therefore reducing the functionality of immune cells in a process known as “immunosenescence” [58].

Aging is associated with low levels of chronic inflammation referred to as “inflammaging”. In the presence of low-grade inflammation, myokines such as interleukin-6 and interleukin-15 activate pro-inflammatory programming leading to muscle catabolism [57]. The regenerative capacity and inflammatory responses in aged muscles are also affected due to impaired homeostasis of regulatory T cells [57]. Although these and other mechanisms explaining the interplay between skeletal muscle and immune cells have been proposed based on in vitro and animal experiments, evidence from clinical studies is limited to cross-sectional associations between inflammatory markers and body composition measures [57]. For example, a recent report from the Copenhagen Sarcopenia Study indicated that concentrations of pro-inflammatory cytokines (i.e., C-reactive protein [CRP], tumor necrosis factor-alpha, interleukin-4, and interferon-γ) increased with aging and were associated with poor physical function; however, only CRP was weakly associated with appendicular lean soft tissue index [59].

Few longitudinal studies with contradicting findings exist to date. In a small prospective cohort study, older adults with high circulating interleukin-6 and CRP levels at baseline had an increased risk of presenting with lower appendicular lean soft tissue after a 5-year follow-up [60]. Although another longitudinal study showed an age-related decline in muscle function, no difference in the incidence of sarcopenia among older adults with a “senescent-like phenotype” compared to a “less senescent-like phenotype” was found [61]. Despite these early clinical findings, immune function is highly relevant in the context of muscle loss, and future studies will confirm or refute these observations.

4. Who is at risk of malnutrition and muscle loss?

4.1. Aging

Poor musculoskeletal health and malnutrition are common among older adults and tied to declining function and the ability to live independently. After the third decade of life, individuals experience an approximately 3%–5% decline in skeletal muscle per decade that is associated with senescence [Fig. 5] [62–66]. Muscle composition also deteriorates with aging, with myosteatosis occurring independently of changes in body weight [67]. The incipient, age-related decline in muscle mass and composition can be accelerated by multiple factors as previously discussed in Sections 2 and 3. A major contributor to malnutrition and muscle loss is anorexia of aging, which is a common term to describe the unintentional decline in nutrient intake later in life [68]. Although adults experience gradual age-related muscle loss, there is some evidence of acute muscle wasting during immobilization even when healthy adults (independent of their age) are provided with adequate energy and protein intakes; but this has been shown to occur more rapidly in older adults [69–71].

4.2. Chronic diseases

Across the healthcare continuum, low muscle mass and malnutrition can overlap and occur as direct consequences of chronic disease or its treatment [3], as observed in renal disease and cancer. Between 11% and 54% of patients with chronic kidney disease are malnourished; the prevalence of sarcopenia has been shown to range between 4% and 42%, depending on the diagnostic criteria used and the patient population [72]. Among patients with cancer, approximately 40% may have low muscle mass, and on average 70% are malnourished [1,73,74]. Muscle loss in chronic illness is progressive over time, but the extent and rate of decline varies across conditions because of the multiple factors affecting the muscle (Fig. 5, Fig. 6) [20]. Furthermore, immobilization and bed rest contribute to an increased rate of muscle wasting among patients with chronic illness [75,76]. The burden of both low muscle mass and malnutrition is common in these patients, highlighting the importance of nutrition interventions to treat and maintain muscle and nutritional status, as both can impact outcomes.

4.3. Critical illness

Muscle loss and malnutrition are also highly prevalent features of critical illness, which is characterized by systemic inflammation [77,78]. Serial ultrasound measurements of cross-sectional area of a quadriceps muscle obtained during the first week of hospitalization in the intensive care unit (ICU) showed early and rapid muscle loss, which is quantitatively more substantial in severely ill patients (Fig. 5) [79]. Myosteatosis identified from computerized tomography (CT) scans upon admission is associated with mortality, independent of muscle mass, and is thus an important marker of muscle

Fig. 4. Factors that accelerate muscle loss. Malnutrition, illness and injury are accelerators of muscle loss. However, the rate of muscle loss is greater (i.e., accelerated) when these factors are combined, leading to severe, more rapid muscle loss.
composition [80]. Regarding malnutrition, between 38% and 78% of critically ill patients are malnourished, which is independently associated with poor clinical outcomes [81]. Muscle wasting, myosteatosis, and malnutrition impact survival and long-term recovery of critically ill patients, underscoring the importance of early and consistent nutrition interventions and monitoring.

4.4. COVID-19

As a new disease, COVID-19 has amplified the relevance of low muscle mass as never before; the loss is severe and may have long-term consequences (Fig. 7 and Fig. S2) [82,83]. In patients with COVID-19, the pooled prevalence of CT-assessed low skeletal muscle mass is 33.6% [84]. Although inconsistencies exist, preliminary results (article under review, personal communications Dr. C. Prado, PhD, RD) of a systematic review on the clinical impact of abnormal body composition in COVID-19 show low muscle mass as a strong predictor of mortality, hospitalization outcomes, mechanic ventilation, disease severity, and ICU admission [85]. The prevalence of abnormal muscle composition (i.e., low muscle radiodensity) ranged between 28.7% and 85.2%. In contrast to muscle quantity findings, low muscle radiodensity was consistently associated with adverse outcomes in these patients [85].
Malnutrition is also highly prevalent in patients with COVID-19, with up to 80% of hospitalized patients either at risk for malnutrition or malnourished and 67% of critically ill patients being malnourished \[86,87\]. The extended periods of reduced nutrient intake, bed rest, and systemic inflammation are common among patients and well-known factors that drive muscle loss and malnutrition in acute and critical illness, which now includes COVID-19. Another factor possibly contributing to malnutrition and muscle loss in this population is hypermetabolism. A recent study has shown that resting energy expenditure increased in critically ill patients with COVID-19 from week 1 to week 3 of mechanical ventilation, and it was maintained until week 7, suggesting specific caloric needs throughout ICU stay, particularly in patients without obesity \[88\]. Persistent hypermetabolism was also demonstrated in another study, with energy expenditure similarly varying across individuals with distinct BMI during ICU stay \[89\].

Importantly, patients can experience long COVID-19 syndrome, a situation where COVID-19-related symptoms extend into recovery \[82\]. These symptoms include fatigue, dyspnea, loss of smell and taste, lack of appetite, nausea, and diarrhea that negatively impact nutrient intake and increase the risk for or exacerbate muscle loss and malnutrition, therefore affecting recovery \(\text{Fig. S3}\) \[90\]. Moreover, patients with no pre-COVID-19 functional deficits experience significant losses in muscle strength and physical function that continue past the acute phase \[91\]. As such, the evidence highlights the importance of multimodal interventions during the acute phase and continuing throughout recovery.

5. Identify at-risk patients

5.1. Advances in malnutrition assessment

Diagnosing malnutrition remains a challenge despite various published diagnostic criteria. To address this issue, the Global Leadership Initiative in Malnutrition (GLIM) published a set of evidence-based, clinically relevant criteria to be used in conjunction with a comprehensive nutritional assessment or validated assessment tools, like the Subjective Global Assessment (SGA), to diagnose adult malnutrition in any healthcare setting \[23,24\]. Thus, GLIM criteria should not replace screening and nutritional assessment: they should be used alongside valid malnutrition risk screening and assessment tools. The working group further suggests practical approaches for the low muscle mass phenotypic criteria \[92,93\]. Figure 8 describes the framework, the phenotypic (non-volitional weight loss, low BMI, and reduced muscle mass) and etiologic (reduced food intake/assimilation and inflammation/disease burden) criteria for the diagnosis of malnutrition and the severity grading of malnutrition, which can be assessed by evaluating the degree of nonvolitional weight loss, BMI, or muscle mass reduction.

5.2. Advances in low muscle mass assessment

Assessing body composition is important for both clinical and research applications, in particular to identify patients with low muscle mass or muscle loss and assess treatment efficacy of anabolic interventions. As a common measure used in clinical settings, BMI is not an indicator of muscle health and therefore, not an appropriate proxy of body composition \[94\]. Several body composition techniques are available to measure or estimate muscle mass \[92,93\]. Each technique has its own advantages, limitations, and factors that need to be considered. Some of these factors include validity (e.g., the extent to which one technique produces comparable measures to the best reference technique), feasibility (e.g., availability, equipment and personnel costs, structure, portability for bedside evaluations), safety (e.g., radiation exposure), and practicality (including patient convenience and setting considerations) \[95,96\].

The overall performance of commonly used methods may differ between research and clinical (inpatient and outpatient) settings \(\text{Fig. 9}\). For example, magnetic resonance imaging (MRI) accurately measures muscle mass at the whole body level, and magnetic resonance-based approaches (e.g., spectroscopy) can be used to determine intramyocellular and extramyocellular lipid content as markers of muscle composition \[97,98\]. Although these methods are useful in research, they are not yet available in clinical settings; advances in data acquisition and analysis may allow their clinical application in the near future. Computerized tomography scans of selected sites are often used in research settings based on clinically obtained images (i.e., from patient’s medical records); yet, prospectively collecting these images solely for muscle mass assessment is not indicated because of high radiation exposure. Notably, although dual-energy X-ray absorptiometry (DXA) does not assess muscle mass; it measures lean soft

---

**Fig. 7.** Interplay of malnutrition, physical inactivity, sarcopenia, and COVID-19 using the substrate and enzyme analogy \[83\]. Malnutrition can be viewed as the substrate (foundation) for sarcopenia, which in turn serves as the substrate for COVID-19. COVID-19 symptoms and consequences can catalyze or worsen the occurrence of sarcopenia, leading to adverse health outcomes. Abbreviation: ICU, intensive care unit.
tissue mass, as further explained in Section 5.2.4. Finally, although anthropometry does not measure body composition, it can be considered useful in clinical settings as a marker of muscle mass. The availability and cost of anthropometric measurements are important considerations, yet the method has poor performance as a research tool.

5.2.1. Bioelectrical impedance analysis and phase angle

Bioelectrical impedance analysis (BIA) estimates muscle mass using population-, equation-, and device-specific prediction equations; these may be potential sources of error when used in individual patients [99,100]. An alternative approach is to use phase angle (PhA), a derived BIA value from resistance and reactance measures, which is becoming an emerging marker of abnormal body composition. Phase angle is an indicator of cell membrane health and integrity and has been used as a prognostic indicator in a variety of conditions, such as survival in patients with cancer [101]. Phase angle has also been associated with markers of inflammation and oxidative stress [102]. Because reactive oxygen species can disrupt cell membrane, there is a recent interest in using PhA as an alternative approach to blood biomarkers of oxidative stress. For example, low PhA predicted 60-day mortality in patients with COVID-19 [103], a condition marked by systemic inflammation and oxidative stress [104].

Research suggests PhA is correlated with muscle area, muscle composition, and associated with a higher risk of dysmobility syndrome, which is defined by a score consisting of six components (i.e., osteoporosis, low lean mass, history of falls, slow gait speed, low handgrip strength and high fat mass) [99,105]. Moreover, a systematic review found the prevalence of sarcopenia was higher in patients with low PhA [106]. Notably, the cut-off values for low PhA are not to be used interchangeably as they are population- and device-specific. Furthermore, factors affecting the ratio between extracellular and intracellular water (i.e., fluid balance) can influence PhA measures [107,108]. These include obesity, edema, physical activity, and other disease-related factors. This creates a challenge as low PhA may be due to modifications in cell mass and hydration, or to impaired cellular function related to disease (e.g. patients with a BMI >40 kg/m² showing lower PhA) [109].

5.2.2. Ultrasound

With the availability of portable measurement devices, ultrasound (US) is a promising tool for muscle mass assessment in clinical practice [110–112]. Research shows US-derived thicknesses of the upper arm and upper thigh were well correlated with measurements of muscle area using CT scans, suggesting it is a suitable, radiation-free alternative to CT [111]. As an example of clinical application, a recent study using US detected a 15% ± 13% reduction in quadriceps muscle thickness of critically ill patients over five days of ICU stay [113]. Ultrasound can also detect muscle echo intensity as a measure of muscle composition in terms of fatty infiltration and the presence of fibrous tissue [114].

Research using US has shown significant differences in muscle thickness and echo intensity in the upper leg and upper abdomen between younger and older adults but not in the upper arm, suggesting age-related changes in muscle are site-specific rather than similar for all muscle groups [112]. Assessing multiple sites may therefore capture changes in muscle parameters to a greater extent than using a single measurement site. However, using several sites may not be practical. As shown in a study of community-dwelling older adults, models including US-derived muscle thickness measured at two sites (i.e., arm and thigh) had sufficient predictive value for appendicular lean soft tissue [115].

Ultrasound technology has evolved in recent years and now includes pocket-sized devices that allow comparable measures of muscle thickness and architecture to those obtained using standard US devices [116]. Nevertheless, the current lack of standardized protocols and cut-off values to identify low muscle mass limit its widespread use in clinical practice. Another challenge is measuring muscle parameters in individuals with obesity or edema, as these conditions have been shown to influence muscle echo intensity [114]. Previous research recommends correcting muscle echo intensity for subcutaneous adipose tissue thickness using a
predefined calibration equation, but whether this equation is applicable to different populations and other US devices remains unclear [117].

5.2.3. Computerized tomography imaging

Using CT scan data to assess body composition has greatly expanded our understanding of the relationship between muscle mass and tolerance to anticancer treatment, complications, and survival, particularly in oncology. However, separating adipose and muscle tissues in a CT scan has historically relied on manual segmentation, which is labor and time intensive and subject to variability. Several software programs are now available for automated CT segmentation, with data showing strong agreement between automated and manual analysis [118]. In addition to being faster than manual segmentation, similar associations with mortality in patients with cancer have been reported [119]. Three-dimensional measurements of muscle, adipose tissue, as well as multiple other tissues and organs is the newest technology for the fully automated CT assessment of body composition [96]. As such, a number of two-dimensional cross-sectional areas (i.e., CT slices) can be quickly quantified with sufficient accuracy and precision [120]. This information can be used with other patient clinical data using artificial intelligence for predictive models of health outcomes [121].

In addition to semi- and fully automated segmentations, other advances have been made to explore the use of CT scans for body composition assessment. For example, regions of interest other than the third lumbar vertebra (the preferred level given its strongest correlations between single-slice areas and total-body muscle and adipose tissue volumes [122]) have been explored when CT scans at this vertebra level is not available [123]. Furthermore, skeletal muscle index reference values are being developed using data from healthy adults, which will improve comparison of prevalence and significance of low muscle mass across different populations [124–128]. Another important CT parameter is muscle radiodensity, a marker of muscle composition of increasing prognostic value [129]. In patients with colorectal cancer, low preoperative muscle radiodensity was associated with greater postoperative length of hospital stay, complication rates, and mortality [130,131]. A systematic review and meta-analysis of 40 studies in patients with cancer highlighted a 73% greater mortality risk in patients with myosteatosis compared to their counterparts [110]. Computerized tomography scan data show myosteatosis has been associated with low muscle strength, poor preoperative physical fitness, muscle metabolic dysfunction, and mortality in different populations [110,132,133]. Myosteatosis has also been associated with greater risk of prediabetes and type 2 diabetes, increased homeostasis model assessment for insulin resistance (HOMA-IR), as well as circulating levels of glucose, insulin, CRP, and interleukin-6 [134]. Also importantly, patients with both myosteatosis and low muscle mass may present at greater risk for poorer outcomes, compared to each of these conditions alone [30,135].

5.2.4. Dual-energy x-ray absorptiometry

As a method to assess body composition, DXA has been widely used in research and clinical settings. This equipment can measure total-body lean soft tissue, fat-free mass (lean soft tissue plus bone mineral content), fat mass, and % fat. DXA has been endorsed for body composition assessment by the GLIM Body Composition Working Group [92,93], and European and Asian sarcopenia working groups [21,22].

As summarized elsewhere, DXA appendicular lean soft tissue has been correlated with MRI and CT measures of skeletal muscle volume [136]. DXA does not directly measure muscle mass; it rather measures lean soft tissue mass, which includes muscle mass but also other tissues and organs (the latter at the whole body level) [19]. Analysis from the Sarcopenia Definitions and Outcomes Consortium did not show consistent associations between DXA

Fig. 9. Diagram summarizing the overall performance of currently available techniques based on their A) accuracy and B) availability of cut-off values for low muscle mass, reliability and feasibility of repeated measures for longitudinal assessments (muscle mass), and associated costs in assessing muscle mass in research, outpatient, and hospital settings. Performance is rated as poor (red face), moderate (yellow face), and sufficient (green face). Abbreviation: BIA, bioelectrical impedance analysis; CT, computerized tomography; DXA, dual-energy X-ray absorptiometry; US, ultrasound. Courtesy of Dr. M.C. Gonzalez. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
measures of lean soft tissue and adverse outcomes in older adults [137,138]. Furthermore, DXA is a costly technique that is also influenced by body thickness, soft tissue hydration, and differences across devices and software versions [19,139,140]. Despite these limitations, DXA is a popular and useful technique as it measures three body compartments and emits low radiation doses. Clinically, DXA is recommended for fat mass assessment, but its validity for assessing lean soft tissue remains unknown [141].

5.2.5. Deuterated creatine dilution
Deuterated creatine (D$_2$Cr) is a novel measure of functional muscle mass — the functional contractile tissue independent of lipid and fibrotic tissue [142]. A single oral dose of D$_2$Cr is absorbed and diluted in the creatine pool in skeletal muscle. Metabolized, enriched D$_2$Cr is determined from a single spot urine collection to estimate muscle mass, i.e., creatine pool size. The method is well correlated with the state-of-the-art MRI; however, it is only moderately correlated with DXA among aging adults [143,144]. A prospective study based on the Osteoporotic Fractures in Men (MrOS) cohort showed strong associations between D$_2$Cr muscle mass (adjusted by body weight) and physical performance, fatigue, risk of injurious falls, mobility limitations, and all-cause mortality; whereas DXA appendicular lean soft tissue (adjusted by height squared) was only positively associated with handgrip strength [145,146]. In spite of being an indirect measure of muscle mass, the method is precise, non-invasive, and safe. However, this analysis relies on the use of high-performance liquid chromatography, a sophisticated analysis that limits its use in clinical practice [147].

5.2.6. Surrogate approaches for assessing muscle mass
Assessing muscle mass should be an integral part of the Nutrition Care Process. When body composition techniques are not available in clinical settings, surrogate approaches can be used, including physical examination for obvious muscle loss and anthropometry (e.g., mid-upper arm circumference and calf circumference) (Fig. 10). Surrogate approaches can help clinicians identify high-risk patients, potentially informing early intervention strategies to alleviate or prevent muscle loss. Handgrip strength and physical performance tests (e.g., sit-to-stand test and gait speed) are techniques commonly employed to assess muscle function in the diagnosis of sarcopenia and frailty; however, they should not be used as surrogate measures of muscle mass (i.e., quantity) [21,22,92,93].

5.2.6.1. Calf circumference. Calf circumference is an anthropometric measure highly correlated with direct and indirect measures of skeletal muscle mass, and therefore it is useful to assess the muscle mass component of the malnutrition and sarcopenia diagnosis [92,93,148–150]. Calf circumference can also be used as a screening tool for case-finding in different populations, when body composition techniques are not available, as endorsed by the 2019 Asian Working Group [22] and the GLIM Body Composition Working Group [92,93]. In addition, calf circumference appears to be more sensitive at identifying age-associated loss of muscle mass than are upper arm circumferences [149,150]. While measuring calf circumference is a valuable tool in inpatient and outpatient settings, a variety of confounding factors can affect measurement and its interpretation, such as age, BMI, ethnicity, and edema.

Adjustment factors for BMI have been published using North-American population representative data including Caucasian, Mexican-Americans, Non-Hispanic Black, and other races/ethnicities healthy adults [Fig. 11] [151]. Calf circumference can be used in adults by applying a simple adjustment factor before comparing it to sex-specific cut-off values [151]. Notably, the BMI-adjustment factor should not be applied to individuals with a BMI <18.5 kg/m$^2$ who have weight or muscle loss, particularly in aging and clinical populations. This is because adjustment factors for people with low BMI (i.e., BMI <18.5 kg/m$^2$) were derived from “healthy” individuals (population-based study) who represented only 2% of the total sample analyzed. As such, these individuals were healthy and young (median age of 27 years), distinguishing them from people in other BMI categories in their study [151], and underweight patients seen in clinical practice. The adjustment factor for this BMI category (rounded value: +4.0 cm) was therefore developed to prevent underestimation of calf muscle in healthy adults when using raw measurements, allowing a direct comparison with suggested cut-off values [151]. As such, no adjustment value should be applied for older adults and clinical populations presenting with a BMI <18.5 kg/m$^2$ who are suspected to have weight or muscle losses, as low muscle mass could be in fact hidden if the adjustment factor is applied. Notably, adjustment factors for lower extremity edema are also available [152]. Notwithstanding, calf circumference may not detect small changes in muscle mass when compared to other body composition techniques, precluding its use in short period of follow-up.

6. Can we prevent or revert muscle loss and malnutrition with nutrition interventions?

Nutrition is central to support muscle anabolism, reduce catabolism, and improve outcomes in patients with muscle loss and malnutrition [153,154]. Moreover, nutrition interventions are most beneficial when they are proactive, initiated early, and continued through recovery, preferably as part of multimodal interventions that also include exercise. Both nutrition and exercise interventions serve as anabolic stimuli to skeletal muscle; however, an additive effect on muscle mass is observed when these strategies are combined, particularly using protein supplementation and resistance exercise [155,156]. For instance, a 12-week multimodal intervention including supervised and home-based exercise programs, protein supplementation, and nurse-led support increased lean soft tissue (by 0.9 kg; standard error: 0.4 kg; p = 0.03) in older patients diagnosed with advanced pancreatic cancer, relative to controls [157]. Maintaining or building muscle mass requires an adequate provision of energy to spare muscle protein and provide adequate substrate for MPS [158]. Interventions in older adults, people with obesity, and patients with highly catabolic conditions, such as cancer cachexia and end-stage renal disease, are particularly challenging because they need to overcome anabolic resistance and disease trajectory to be effective [159]. As recently reviewed, differences in anabolic resistance exist across populations, and research has focused on dietary strategies addressing the post-prandial period to maximize anabolic potential [159]. Likewise, nutrients such as protein/amino acids, vitamin D, n-3 polyunsaturated fatty acids (n-3 PUFA), β-hydroxy-β-methylbutyrate (HMB), and polyphenols can support muscle health and recovery by affecting both muscle and immune function, demonstrating the interaction between muscle and immune systems. These and other nutritional strategies are actively being explored in nutrition intervention trials focusing on muscle mass, sarcopenia and cachexia [160]. Because achieving nutritional intake goals in older adults and clinical populations may be challenging, individualized nutritional counseling should be offered concurrent to nutrition therapy, as endorsed by nutrition care guidelines [161,162].

6.1. Protein and amino acids

Protein and amino acids support muscle by providing substrates for MPS and the immune system by converting pro-inflammatory M1 macrophages to the anti-inflammatory form, M2 [163]. The
Ability of dietary proteins to stimulate MPS primarily depends on their essential amino acid (EAA) content and rate of protein digestion. Studies in humans show transient increases in MPS, peaking 45–90 min after ingestion of a bolus of protein high in EAAs, with excess amino acids remaining in the circulation [164,165]. This suggests muscle has an intrinsic capacity to recognize when it has taken in enough amino acids at a given period to replace those lost during the intervening fasting periods [164,165]. Interestingly, after 90–180 min, MPS returns to baseline, which indicates that muscle is only transiently responsive to the intake of dietary protein, particularly in relation to its EAA content [166].

Compared to plant sources of protein, animal-derived proteins have a higher digestibility and provide EAAs required for MPS (including a greater content of leucine) [167]. Consequently, studies have shown greater anabolic effect of animal-based protein on MPS than plant-based proteins at both rest and after exercise conditions [168–170]. For instance, soy protein was found to be less effective than whey protein in stimulating MPS and had no effect on MPS at rest with 40g of soy protein isolate in older men [170]. Blending plant- and animal-derived proteins may enhance the anabolic effect of plant proteins thereby increasing and extending MPS through correction of EAA deficiencies and the different rates of digestion between protein sources, suggesting any rate-limiting issues would be minimized [167].

In contrast to whey protein, collagen protein hydrolysate supplementation alone does not elicit an acute response on MPS as it is an incomplete protein [165,171–173]. A small crossover study testing the effects of supplementing the diet (0.8 g/kg body weight/d of protein) with either collagen or whey protein for 15 days reported no changes in lean soft tissue of older women; although nitrogen balance was maintained with collagen, nitrogen excretion was higher with whey protein supplementation [174]. Collagen is rich in non-EAAs, which may explain its positive effects on nitrogen balance [165]. Moreover, a mixed blend of collagen and milk protein induced MPS to a similar extent as milk protein alone, and also exhibited a greater increases in mammalian target of rapamycin (mTOR) signaling in spite of lower leucine content [175].

Finally, more research is needed to understand the proportion of animal- and plant-base protein sources that should make up protein recommendations in the malnutrition and muscle health contexts. An expert group paper discussing protein sources for patients with cancer has suggested that although both animal and...
plant protein sources are needed, 65% or more of protein intake should come from animal sources during treatment for such a highly catabolic condition [176]. This remains to be investigated in this and other clinical scenarios.

6.2. Branched-chain amino acids: focus on leucine

Leucine is a branched-chain amino acid. Compared to other EAAs, leucine is perhaps the most potent anabolic one [177]. Feeding 3 g leucine daily to healthy young men is associated with a pronounced increase in MPS, even in the absence of other amino acids, suggesting a recognition system of leucine as a marker of protein intake [178]. Furthermore, results of a meta-analysis indicated that leucine supplementation was effective in increasing measures of muscle mass (assessed as lean soft tissue and fat-free mass) in older adults [179]. Despite these findings, supplementation with leucine or branched-chain amino acid alone may not stimulate the maximal response of MPS as they lack other EAA [155].

6.3. β-hydroxy-β-methylbutyrate (HMB)

β-hydroxy-β-methylbutyrate is a bioactive anabolic metabolite of leucine that is synthesized in muscle and found in small amounts in the diet. When orally consumed, HMB exerts similar anabolic effects on MPS as leucine. Interestingly, supplementation with HMB has been shown to suppress MPB to a greater degree than does leucine [178]. Although the impact of HMB supplementation on muscle mass and strength has not been positive in all studies [180], overall findings are promising. A systematic review and meta-analysis of 15 randomized controlled trials (RCTs) conducted in a variety of clinical conditions showed that HMB supplementation is associated with improved muscle mass and strength; however, the effect size was small [181]. In patients with cancer, higher quality studies also support a beneficial effect of HMB supplementation on improving muscle mass and function, decreasing hospitalization, and improving survival in patients with cancer, in spite of the limited evidence [182].

6.4. Vitamin D

Vitamin D is a fat-soluble vitamin well recognized for its role in bone and muscle health. Research has demonstrated the link between vitamin D deficiency and muscle dysfunction, possibly due to the loss of vitamin D receptor function, increased oxidative stress and impaired mitochondrial function [183]. There is also evidence of a longitudinal association between low vitamin D status and sarcopenia [184]. Moreover, vitamin D affects immunity, and it has been shown to downregulate the expression of pro-inflammatory cytokines, increase the proliferation, differentiation and growth of muscle, and increase naturally occurring regulatory T cells involved in modulating immune response [185,186]. Findings from
systematic reviews and a meta-analysis suggest beneficial effects of vitamin D supplementation on muscle strength and physical performance, but not on muscle mass in older adults [187–189].

6.5. Long chain n-3 polyunsaturated fatty acids (n-3 PUFA)

As a class of fatty acids, n-3 PUFA exert anti-inflammatory effects that strengthen crosstalk between skeletal muscle and immune system cells to promote muscle anabolism [163]. In vitro research shows n-3 PUFAs’ anti-inflammatory effects reduce cytokine-mediated loss of specific muscle proteins and cell death to promote anabolism by inhibiting proteolysis [163]. Daily supplementation with n-3 PUFA is associated with improving muscle mass and physical performance in healthy aging adults [190]. Improvements in muscle composition have also been observed in patients with cancer receiving omega 3 supplementation [191,192]. A meta-analysis also reported a positive effect of n-3 PUFA supplementation on measures of muscle mass (i.e., lean soft tissue, fat-free mass, skeletal muscle) and lower-body strength (i.e., quadriceps maximum voluntary capacity) in healthy and clinical populations [193]. Nonetheless, in patients with cancer, another meta-analysis showed no effects of n-3 PUFA supplementation (alone or in oral nutritional supplements [ONS]) on improving muscle mass, body weight, and quality of life; however, the likelihood of developing chemotherapy-induced peripheral neuropathy was reduced in those who received n-3 PUFA supplements [194]. As studies included in both meta-analyses were substantially heterogeneous regarding population, supplement dosage/duration, and outcome assessment, future well-designed RCTs should be conducted to clarify the effects of n-3 PUFA supplementation in different populations.

6.6. Polyphenols

Similar to n-3 PUFA, polyphenols have anti-inflammatory properties that may modify the crosstalk between muscle and immune cells. In this sense, polyphenols reduce signaling by nuclear factor kappa B, thus diminishing the inflammatory response to improve muscle synthesis [163]. However, to date, the evidence on the effects of polyphenol supplements on muscle health in older adults and clinical populations is limited. For example, one small RCT showed no additional benefit of Montmorency cherry concentrate to resistance exercise combined with whey protein supplementation on MPS in healthy older men [195]. Furthermore, intervention with reseratrol led to increased mitochondria number and downregulation of genes associated with adverse mitochondrial bioenergetics in muscle samples from older adults, but did not improve glucose metabolism or insulin sensitivity in older adults with impaired glucose tolerance [196].

6.7. Oral nutritional supplements (ONS)

In addition to improving food intake, the use of ONS is a cornerstone for preventing and treating muscle loss and malnutrition; ONS contain additional protein, energy, and micronutrients and potentially other specialized nutrients or ingredients previously described to support muscle health and improve nutritional status. Research has shown that supplementation with ONS improves energy, protein, and micronutrient intakes beyond food alone [197,198].

Several RCTs have been performed to evaluate the effects of ONS on health outcomes of older adults and clinical populations [199–201]. For instance, one RCT compared the effect of dietary counseling with either an ONS containing HMB (ONS-HMB) or placebo beverage for six months on nutritional and functional outcomes in a large sample of community-dwelling older adults at risk for malnutrition (n = 811) [202]. The study showed the proportion of participants not admitted or readmitted to the hospital and those who gained at least 5% body weight at six months was greater in the ONS-HMB group versus placebo (33% vs 9%, p < 0.001), and consuming ONS-HMB was associated with greater improvements in serum 25-hydroxyvitamin D levels, leg strength, grip strength in women, and improved energy and protein intakes [202]. Another large RCT also indicated beneficial effects of a protocol-guided individualized nutrition support in hospitalized patients at risk of malnutrition, with 91% of patients in the intervention arm receiving ONS for 30 days [203]. The intervention was associated with a decreased risk of adverse clinical outcomes and all cause-mortality, and it also improved quality of life and functional status, compared to a placebo group receiving standard care (i.e., hospital food). Furthermore, findings from a narrative review support the efficacy of a whey protein ONS (enriched with leucine and vitamin D) for patients with or at risk of sarcopenia (i.e., community dwelling older adults, patients at rehabilitation units and care homes, and individuals with sarcopenic obesity) to increase skeletal muscle and related body compartments [204]. Studies in clinical settings have similarly supported the use of ONS in improving muscle mass or composition. For example, one RCT explored the impact of ONS with dietary advice in post-discharge patients at nutritional risk following cancer surgery [205]. After 3 months, the intervention group presented with a lower prevalence of low muscle mass, compared to the control group [205].

6.8. Nutraceuticals

Several nutraceuticals may exert positive effects on muscle anabolism, strength, and function. These include creatine, carnitine, and β-alanine to improve bioenergetics either at rest or under exercise conditions, nitrates to improve vascular function, and the biologics phosphatidic and ursolic acids, which have been shown to trigger growth pathways in muscle [206–209]. However, further research is required to evaluate these compounds and their efficacy on muscle health in individuals with or at risk for muscle loss either due to aging, malnutrition, or disease.

7. Adjuvant exercise interventions

It is important to acknowledge the significance of regular exercise, preferably in combination with nutrition interventions as a multimodal approach across the continuum of care. A systematic review of 37 RCTs compared the effect of nutrition combined with regular exercise vs exercise alone on muscle mass and function in healthy older adults [188]. Exercise was found to improve muscle mass, strength and physical performance; however, additional benefits of concurrent nutrition intervention are unclear [188]. A pooled analysis of studies offering protein supplements and/or higher protein diets to older adults revealed that only interventions combining nutrition and resistance exercise benefited appendicular lean soft tissue and handgrip strength [210]. For instance, a four-arm RCT has demonstrated the synergistic effect of combining resistance exercise training, protein, and vitamin D in older adults with sarcopenia or dynapenia (i.e., low muscle function alone) [211]. Participants receiving all three interventions showed greater improvements on muscle echo intensity, PhA, and knee extension torque, compared to each isolated intervention or no intervention [211]. In addition to its positive effects on muscle quantity and composition and cardiovascular function, regular exercise improves
immune function via myokines like interleukin-15 that also stimulates myogenesis and reduces adiposity, thereby affecting body composition [212,213].

Evidence suggests that both resistance and endurance-based exercises have a beneficial effect on mitochondrial health and function by reducing oxidative damage, improving oxidative coupling ability, increasing mitochondrial and mitochondrial protein genesis [214]. As such, exercise may play a key role in mediating the impact of mitochondrial dysfunction and poor muscle health. Fig. S4 depicts an analogy of the importance of both nutrition and exercise interventions to be used in patient educational materials.
8. Healthy aging: shifting the focus from waiting for frailty to living with strength

Not all older adults will develop frailty. The paradigm of healthy aging should focus on maintaining good health and the ability to live meaningful and independent lives for as long as possible (Fig. 12). This includes optimizing nutrition and exercise to avoid age-related muscle loss that can progress to frailty, dysmobility syndrome, and loss of independence. Studies suggest home-based interventions that combine exercise and nutrition can indeed improve frailty scores and physical performance and increase the number of days in a month in which physical and mental health are described as overall good [215–217]. In addition to health benefits, lifestyle programs in community-dwelling adults are also cost-effective interventions, emphasizing their economic impact to public health costs [217–219].

9. Recommendations for clinical practice

To ensure at-risk patients are consistently screened, assessed, treated, and monitored, we offer the following clinical practice recommendations:

- **Advance screening, assessment, and diagnostic practices for low muscle mass and malnutrition** — Screening helps to identify at-risk individuals who require further assessment and treatment for muscle loss and malnutrition. Assessing muscle mass should be an integral part of the Nutrition Care Process, and it starts with nutrition screening. The SARC-F and SARC-CalF tools can be used to screen for sarcopenia in older adults [220]. Several validated tools are available to screen for malnutrition risk, such as the Malnutrition Universal Screening Tool (MUST), the Malnutrition Screening Tool (MST), and the Nutrition Risk Screening 2002 (NRS-2002) [221–223]. Using validated assessment tools within the GLIM framework (Fig. 8) for malnutrition diagnoses and the proper use and interpretation of body composition assessment (to identify low muscle mass) should be reinforced in patient care pathways. Efforts from the GLIM Body Composition Working Group will facilitate the latter [92,93]. Additionally, the ongoing COVID-19 pandemic and the increased use of telehealth highlighted the relevance and need for digital tools such as the R-MAPP (Remote – Malnutrition APP) for screening, assessment, and monitoring patients remotely [224].

- **Use of surrogate tools to identify low muscle mass in the absence of body composition techniques** — As not all body composition assessment methods are available in all clinical settings, surrogate markers of muscle mass can be implemented (Fig. 10). As discussed previously, calf circumference is an anthropometric measure that correlates well with muscle mass, requires minimal training, and is a useful tool in clinical practice. Measuring calf circumference to identify low muscle mass can also be used in conjunction with validated assessment tools within the GLIM framework to help diagnose malnutrition.

- **Promote multimodal care** — The pathophysiology of muscle loss is multifactorial, and so is the need for a multidisciplinary approach to prevent/halt this condition. Physicians, dietitians, nurses, exercise physiologists and/or physical and occupational therapists all have a role to play.

- **Provide nutrition education for patients, families and caregivers** (Fig. 13) — Increasing awareness of low muscle and malnutrition and improving patients’ knowledge on early signs of muscle loss and malnutrition are key. According to a survey, older adults with varied appetite and protein intake levels considered one meal containing a good protein source to be sufficient for achieving their daily protein needs, emphasizing the need for nutrition education [225]. Furthermore, older adults may be unaware of the importance of snacking and eating in the absence of hunger, as well as the consequences of weight and muscle losses [226,227]. Limited health care professional knowledge of the nutritional needs and concerns of older adults and clinical populations may also hinder adequate nutrition intervention [228]. Healthcare professionals should also be aware that muscle loss can occur in the absence of changes in body weight, particularly in older adults with obesity [229]. Institutions and healthcare professionals (supported by patients’ families and caregivers) have a duty to implement educational strategies related to preventing malnutrition and muscle loss (Fig. 13). This includes but is not limited to verbal and/or written advice and plain-language resources on how to increase caloric and protein intakes, lectures, workshops, group discussions, and cooking courses [230]. Please refer to the Supporting File which contains a separate sets of figures clinicians can use to individualize educational booklets, presentations, and online resources.

10. Outlook on future research

Research is needed to understand the benefit of integrating body composition assessment into clinical practice, and the impact of using this information to personalize nutrition interventions to prevent and treat low muscle mass and malnutrition. Specific immunological and muscle-related targets should be explored, which may transform the understanding and treatment of low muscle mass. Furthermore, more research is required to explore the impact of nutrition and exercise interventions to maximize anabolic potential, physical performance, and outcomes in healthy aging, and acute and chronic disease, including acute conditions like COVID-19. Recommendations for future nutrition trials have been provided in order to rapidly advance knowledge translation of interventions addressing muscle, sarcopenia and cachexia to clinical practice [160].

11. Conclusion

Clinical practice is changing, and healthcare professionals are encouraged to implement many of the tools hereby discussed to assess muscle loss and malnutrition in their settings. Muscle loss and malnutrition can be hidden from view, yet screening is the only means of identifying at-risk individuals; assessment can diagnose the presence and severity of low muscle mass and/or malnutrition. Several nutrition interventions including individual nutrients or ingredients, bioactive ingredients, and ONS have been shown to improve muscle mass, composition, and function (muscle health) and can be important tools to addressing muscle loss [154]. Importantly, combining nutrition interventions with exercise as components of a multimodal approach is an important strategy to improving patient outcomes.

**Author contribution**

All authors were responsible for conceptualization, writing, review and editing.

**Funding statement**

Abbott Nutrition provided support and funding for the Abbott Nutrition Research Conference and this publication.
Conflict of interest

C.M.P. has previously received honoraria and/or paid consultancy from Abbott Nutrition, Nutricia, Nestlé Health Science, Fresenius Kabi, and Pfizer. T.R. reports grants from German Ministry of Education, Science, Research and Technology; grants and personal fees from Sanofi-Aventis and Alexion; personal fees from Abbott Nutrition, Argenx, Biogen, BMS, Roche, Novartis, and Teva; and personal fees and nonfinancial support from Merck Serono, outside the submitted work. S.T.H.C has previously received grant co-funding, travel grant and honoraria from Abbott Nutrition. M.G.G. has received paid consultancy from Abbott Nutrition and Nestlé Nutrition Brazil. F.L., P.J.A, J.M., T.B. have previously received grant funding and paid consultancy from Abbott Nutrition.

Acknowledgments

We thank Carolyn Alish and Camila E Orsso who provided medical writing and illustration services in the development of this article.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.clnu.2022.07.041.

References


2260


